Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.085 USD | 0.00% | -14.05% | -34.46% |
May. 06 | PURE Bioscience Appoints Darin Zehr to Board of Directors | CI |
Mar. 22 | PURE Bioscience, Inc. announced that it has received $3 million in funding | CI |
Valuation
Fiscal Period: July | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 38.28 | 24.56 | 124.3 | 36.63 | 22.24 | 9.508 |
Enterprise Value (EV) 1 | 37.93 | 24.17 | 120.4 | 34.48 | 18.85 | 9.434 |
P/E ratio | -5.07 x | -3.61 x | 30,426 x | -14 x | -5.08 x | -2.39 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 21.6 x | 12.9 x | 18 x | 9.33 x | 12 x | 5.07 x |
EV / Revenue | 21.4 x | 12.7 x | 17.4 x | 8.78 x | 10.2 x | 5.03 x |
EV / EBITDA | -5.79 x | -4.52 x | 614 x | -16.1 x | -5.87 x | -2.69 x |
EV / FCF | -12.8 x | -28.1 x | 196 x | -42.3 x | -14.9 x | -4.84 x |
FCF Yield | -7.81% | -3.56% | 0.51% | -2.37% | -6.72% | -20.6% |
Price to Book | 29.9 x | 21 x | 25.9 x | 11 x | 5.69 x | 35 x |
Nbr of stocks (in thousands) | 68,229 | 75,582 | 86,891 | 87,223 | 111,356 | 111,856 |
Reference price 2 | 0.5610 | 0.3250 | 1.430 | 0.4200 | 0.1997 | 0.0850 |
Announcement Date | 10/25/18 | 10/30/19 | 10/8/20 | 10/28/21 | 10/28/22 | 10/30/23 |
Income Statement Evolution (Annual data)
Fiscal Period: Juli | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 1.774 | 1.909 | 6.917 | 3.927 | 1.853 | 1.877 |
EBITDA 1 | -6.554 | -5.348 | 0.196 | -2.139 | -3.212 | -3.511 |
EBIT 1 | -6.839 | -5.589 | 0.004 | -2.311 | -3.425 | -3.628 |
Operating Margin | -385.51% | -292.77% | 0.06% | -58.85% | -184.84% | -193.29% |
Earnings before Tax (EBT) 1 | -7.442 | -6.554 | 0.004 | -2.319 | -3.491 | -3.961 |
Net income 1 | -7.442 | -6.554 | 0.004 | -2.319 | -3.491 | -3.961 |
Net margin | -419.5% | -343.32% | 0.06% | -59.05% | -188.4% | -211.03% |
EPS 2 | -0.1106 | -0.0899 | 0.000047 | -0.0300 | -0.0393 | -0.0356 |
Free Cash Flow 1 | -2.962 | -0.8599 | 0.6144 | -0.8159 | -1.267 | -1.947 |
FCF margin | -166.99% | -45.04% | 8.88% | -20.78% | -68.4% | -103.74% |
FCF Conversion (EBITDA) | - | - | 313.46% | - | - | - |
FCF Conversion (Net income) | - | - | 15,359.38% | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 10/25/18 | 10/30/19 | 10/8/20 | 10/28/21 | 10/28/22 | 10/30/23 |
Balance Sheet Analysis
Fiscal Period: July | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 0.35 | 0.4 | 3.84 | 2.15 | 3.39 | 0.07 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -2.96 | -0.86 | 0.61 | -0.82 | -1.27 | -1.95 |
ROE (net income / shareholders' equity) | -579% | -530% | 0.13% | -56.9% | -96.4% | -189% |
ROA (Net income/ Total Assets) | -133% | -155% | 0.06% | -27.2% | -48.7% | -71.9% |
Assets 1 | 5.575 | 4.228 | 6.612 | 8.53 | 7.165 | 5.51 |
Book Value Per Share 2 | 0.0200 | 0.0200 | 0.0600 | 0.0400 | 0.0400 | 0 |
Cash Flow per Share 2 | 0.0100 | 0.0100 | 0.0400 | 0.0300 | 0.0300 | 0.0100 |
Capex 1 | 0.02 | 0.01 | 0.06 | 0.52 | 0.08 | 0.03 |
Capex / Sales | 1.07% | 0.37% | 0.84% | 13.27% | 4.37% | 1.76% |
Announcement Date | 10/25/18 | 10/30/19 | 10/8/20 | 10/28/21 | 10/28/22 | 10/30/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-34.46% | 9.51M | |
-15.26% | 41.09B | |
+12.48% | 26.01B | |
-4.89% | 16.84B | |
-23.23% | 6.48B | |
+7.71% | 6.08B | |
-0.17% | 3.23B | |
+1.03% | 2.35B | |
+23.63% | 948M | |
-1.20% | 645M |
- Stock Market
- Equities
- PURE Stock
- Financials PURE Bioscience, Inc.